CORRECTING and REPLACING - SteadyMed Reports Recent

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CORRECTING and REPLACING - SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results

SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SteadyMed Ltd. (Nasdaq: STDY ), please note that in the first paragraph under the First Quarter 2015 Financial Results heading, GAAP net loss attributable to ordinary shareholders should be $6.5 million, not $5.6 million as previously stated. The corrected release follows: SteadyMed Ltd. (Nasdaq: STDY ), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, today announced recent developments, financial highlights and financial results for the first quarter ended March 31, 2015.

"SteadyMed has met key objectives in early 2015 and we remain on track to submit an NDA for our lead product candidate Trevyent ® , for the treatment of pulmonary arterial hypertension, in Q1 2016," said Jonathan M. N. Rigby, President and Chief Executive Officer of SteadyMed. "We filed for Orphan Drug Designation and successfully completed an additional Human Factors study for Trevyent, strengthened our patent portfolio and built out our senior management team. We raised over $50 million in Q1 2015, completing both a mezzanine Series E financing and an IPO, and continue to expect that these proceeds will enable us to meet our strategic goals through at least mid-2016."

Recent Developments

  • In April, SteadyMed filed an application for Orphan Drug Designation for Trevyent with the U.S. Food and Drug Administration (FDA).  
  • In April, SteadyMed announced the issuance of a new patent from the United States Patent and Trademark Office (USPTO) and receipt of a Patent Term Extension for an additional 705 days affording additional intellectual property protection through June 2028 for its PatchPump platform technology, which is the drug administration system for Trevyent.  
  • In April, SteadyMed further strengthened its executive management team with the appointment of David Nassif as its full time Chief Financial Officer.  
  • In February, SteadyMed successfully completed its seventh in a series of eight planned Human Factors Studies for Trevyent. These studies are designed to ensure that Trevyent is safe, and usable by patients with pulmonary arterial hypertension (PAH) and their healthcare providers. This program of studies was initiated in 2013 and has involved 118 subjects to date.

Recent Financial Highlights

  • In March, SteadyMed raised net proceeds of approximately $34.8 million in its initial public offering (IPO) from the sale of 4,700,000 ordinary shares. The company's shares began trading on the NASDAQ Global Select Market under the symbol "STDY".  
  • In January, SteadyMed raised $12.2 million in a third closing of it Series E financing round co-led by funds advised by subsidiaries of Federated Investors Inc. and Deerfield Management Company L.P., and the company's largest existing shareholders also participated in the financing.

First Quarter 2015 Financial Results

For the first quarter ended March 31, 2015, SteadyMed reported a GAAP net loss attributable to ordinary shareholders of $6.5 million, or $4.35 per share, basic and diluted, compared to a net loss attributable to ordinary shareholders for the first quarter ended March 31, 2014 of $2.8 million, or $6.74 per share, basic and diluted. The current quarter's calculation used 1,503,708 weighted-average shares outstanding, versus 501,828 outstanding shares in the prior-year period. Included in the first quarter 2015 net loss per share is a non-cash, nonrecurring charge of approximately $0.9 million related principally to an assumed dividend on the company's convertible preferred stock triggered by an assumed liquidation event prior to the IPO. All of the company's previously outstanding convertible preferred stock automatically converted into ordinary shares upon the closing of the company's IPO on March 25, 2015 (without the occurrence of the assumed liquidation event).

Total operating expenses for the first quarter ended March 31, 2015 were $5.5 million compared to $2.8 million for the quarter ended March 31, 2014.

Research and development (R&D) expenses for the first quarter of 2015 were $4.4 million, compared to $2.3 million for the first quarter of 2014. The increase in R&D expenses year-over-year was primarily due to increased use of sub-contractor services for the Trevyent development and scale up program.

General and administrative (G&A) expenses were $0.9 million for the first quarter of 2015, compared to $0.4 million for the same period in 2014. The increase in year-over-year G&A expenses was primarily due to the additional consulting and professional services expenses incurred in preparation for and completion of the company's IPO.

Cash and cash equivalents were $48.9 million as of March 31, 2015.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on March 19, 2015. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

STEADYMED LTD. AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
 
  Three Months Ended March 31,
  2015 2014
  Unaudited
     
Operating expenses:    
Research and development  $ 4,409  $ 2,251
Marketing  222  219
General and administrative  905  363
Total operating loss  5,536  2,833
     
Financial income, net  (103)  (81)
     
Loss before taxes on income  (5,433)  (2,752)
Taxes on income  123  45
Net loss  $ (5,556)  $ (2,797)
     
Net loss per share:    
     
Basic and diluted net loss per Ordinary Share  $ (4.35)  $ (6.74)
     
Weighted-average number of Ordinary Shares used to compute basic and diluted net loss per share  1,503,708  501,828
     
STEADYMED LTD. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS 
(U.S. dollars in thousands, except share and per share data)
 
  March 31, 2015 December 31, 2014
  Unaudited
Assets:    
Cash and cash equivalents  $ 48,893  $ 6,167
Other assets  2,964  4,159
Total assets  $ 51,857  $ 10,326
     
Liabilities and shareholders' equity (deficit):    
Liabilities  $ 5,604  $ 10,978
Convertible preferred shares  --   35,669
Shareholders' equity (deficit)  46,253  (36,321)
Total liabilities, convertible preferred shares & shareholder's equity (deficit)  $ 51,857  $ 10,326

Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 Robert H. Uhl Managing Director Westwicke Partners 858-356-5932

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 112

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 140

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 109

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 100

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 111

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading

Top 5 Most Recently Viewed Articles

SiriusPoint Declares Cash Dividend on Series B Preference Shares

Updated Category News Views 123

SiriusPoint Declares Quarterly Cash Dividend for Investors In a significant move for its shareholders, SiriusPoint Ltd. has recently revealed the approval of a quarterly cash dividend of $0.50 per share for the 8.00% Resettable Fixed Rate Preference Shares, Series B. This decision, endorsed by the Audit Committee of the Board of Directors, showcases the company's...

Continue Reading
Urban One Welcomes New Leadership as CEO David Kantor Retires

Updated Category News Views 435

Changes in Leadership at Urban One Urban One has made a significant announcement regarding changes at the helm of its audio division. Currently, the company bids farewell to CEO David Kantor, a well-respected figure in the industry, whose tenure has shaped Urban One into a key player in audio entertainment. Kantor's retirement, set for early 2025, opens the door for new...

Continue Reading
Mattamy Homes Expands Presence with New Division in Florida

Updated Category News Views 502

Mattamy Homes Expands Operations in Florida Company strengthens regional focus to enhance customer service, empower teams and drive future expansion Mattamy Homes US has officially launched a new division centered in Southwest Florida. This strategic initiative is set to improve operational agility, allowing Mattamy to provide exceptional service to its customers...

Continue Reading
Eloro Resources Secures $3.78 Million in Latest Placement

Updated Category News Views 235

Eloro Resources Completes Private Placement Successfully Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) has announced a significant achievement in its funding efforts. The company successfully closed its non-brokered private placement offering, concluding with a total of 4,200,000 units sold. This move resulted in gross proceeds of approximately $3,780,000,...

Continue Reading
Groundbreaking Global Health Exhibition Set to Transform Healthcare

Updated Category News Views 54

Global Health Exhibition Promises Unmatched Innovation Tomorrow marks the opening of the much-anticipated Global Health Exhibition, an international healthcare event attracting over 100,000 professionals dedicated to health and patient care. Spanning across three days, this premier event will host an impressive assembly of over 1,200 exhibiting companies and brands,...

Continue Reading